Regional lymph node (LN) involvement significantly impacts the prognosis and treatment of rhabdomyosarcoma (RMS) in children. However, determining LN involvement without biopsy remains challenging. Although 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET) exhibits higher sensitivity and specificity than conventional imaging (i.e., CT and MRI), its ability to accurately determine regional lymph node involvement in RMS specifically remains unclear. Without pathologic assessment, regional lymph nodes are often presumed to be positive based if >1 cm on cross-sectional imaging or if avid lymph nodes on FDG-PET/CT, which can then impact recommended treatment and associated morbidity. This study aims to assess the correlation between lymph node size in cross-sectional imaging and FDG-PET avidity with pathologic findings in RMS patients, thereby defining the role of FDG-PET in regional lymph node staging.
Study Investigators: Daniel Rhee MD, MPH
Contact Chloé Boehmer (Chloe.Boehmer@cchmc.org) if you have any questions on how your site can participate in this study.
Comments